Exchange: NYSEMkt·Updated 07:59 PM EDT
News
all
press releases
ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?
ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.
Zacks
More News
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of -66.67% and -19.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates
Teleflex (TFX) delivered earnings and revenue surprises of +37.50% and +1.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of +40.00% and +1.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Integer (ITGR) Surges 20.2%: Is This an Indication of Further Gains?
Integer (ITGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Can ISRG Defend Its Leadership as Global Competition Intensifies?
ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price.
Zacks
ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?
ISRG is set to report Q2 results on July 16, with sales and EPS expected to rise, while investors weigh margin pressure against strong adoption of da Vinci 5.
Zacks
ISRG's Capital Placement Surge: Demand Strength or Upgrade Cycle Peak?
ISRG placed 431 da Vinci systems in Q1 2026, but rising trade-ins and leasing growth raise questions about whether demand is structural or upgrade-driven.
Zacks
ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?
ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.
Zacks

Advertisement|Remove ads.